The potential and promise for clinical application of adoptive T cell therapy in cancer

Yinqi Li,Yeteng Zheng,Taiqing Liu,Chuanyun Liao,Guobo Shen,Zhiyao He

DOI: https://doi.org/10.1186/s12967-024-05206-7

IF: 8.44

2024-05-04

Journal of Translational Medicine

Abstract:Adoptive cell therapy has revolutionized cancer treatment, especially for hematologic malignancies. T cells are the most extensively utilized cells in adoptive cell therapy. Currently, tumor-infiltrating lymphocytes, T cell receptor-transgenic T cells and chimeric antigen receptor T cells are the three main adoptive T cell therapies. Tumor-infiltrating lymphocytes kill tumors by reinfusing enlarged lymphocytes that naturally target tumor-specific antigens into the patient. T cell receptor-transgenic T cells have the ability to specifically destroy tumor cells via the precise recognition of exogenous T cell receptors with major histocompatibility complex. Chimeric antigen receptor T cells transfer genes with specific antigen recognition structural domains and T cell activation signals into T cells, allowing T cells to attack tumors without the assistance of major histocompatibility complex. Many barriers have been demonstrated to affect the clinical efficacy of adoptive T cell therapy, such as tumor heterogeneity and antigen loss, hard trafficking and infiltration, immunosuppressive tumor microenvironment and T cell exhaustion. Several strategies to improve the efficacy of adoptive T cell therapy have been explored, including multispecific chimeric antigen receptor T cell therapy, combination with immune checkpoint blockade, targeting the immunosuppressive tumor microenvironment, etc. In this review, we will summarize the current status and clinical application, followed by major bottlenecks in adoptive T cell therapy. In addition, we will discuss the promising strategies to improve adoptive T cell therapy. Adoptive T cell therapy will result in even more incredible advancements in solid tumors if the aforementioned problems can be handled.

medicine, research & experimental

What problem does this paper attempt to address?

The paper primarily explores the potential applications and challenges of Adoptive T cell therapy (ACT) in cancer treatment. It provides a detailed introduction to several major types of adoptive T cell therapies, including Tumor-infiltrating lymphocytes (TILs), T cell receptor-transgenic T cells, and Chimeric antigen receptor T cells (CAR T cells).

1. **Tumor-infiltrating lymphocytes (TILs)**: This therapy involves extracting and expanding T cells from the patient that can recognize tumor-specific antigens to treat cancer. Although TILs have shown good efficacy in melanoma, their effectiveness in other solid tumors still needs improvement.
2. **T cell receptor-transgenic T cells (TCR-T cells)**: This therapy uses genetic engineering to make T cells express T cell receptors that can specifically recognize tumor antigens. It can target Tumor-associated antigens (TAAs) or Tumor-specific antigens (TSAs), but there is a certain risk of on-target off-tumor toxicity.
3. **Chimeric antigen receptor T cells (CAR T cells)**: This therapy involves genetically modifying T cells to express chimeric antigen receptors that can directly recognize antigens on the surface of tumor cells, without relying on the Major histocompatibility complex (MHC). CAR T cells have already achieved significant efficacy in hematologic malignancies.

The paper also discusses the main bottlenecks currently faced by ACT, such as tumor heterogeneity, antigen loss, and the immunosuppressive microenvironment. It proposes several strategies to improve ACT efficacy, such as multi-specific CAR T cell therapy, combination with immune checkpoint inhibitors, and targeting the immunosuppressive microenvironment. If these issues can be overcome, ACT will achieve more breakthroughs in the treatment of solid tumors.